Literature DB >> 27749322

Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.

Daniel C Danila1, Aliaksandra Samoila, Chintan Patel, Nicole Schreiber, Amrita Herkal, Aseem Anand, Diogo Bastos, Glenn Heller, Martin Fleisher, Howard I Scher.   

Abstract

Circulating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administration-cleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)-based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%-75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%-81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%-58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5-1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27749322      PMCID: PMC5108569          DOI: 10.1097/PPO.0000000000000220

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  20 in total

Review 1.  Biomarker development in the context of urologic cancers.

Authors:  Gary J Kelloff; Caroline C Sigman; Howard I Scher
Journal:  Urol Oncol       Date:  2015-03-05       Impact factor: 3.498

2.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

3.  Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Authors:  Daniel C Danila; Aseem Anand; Nikolaus Schultz; Glenn Heller; Mingliang Wan; Clifford C Sung; Charles Dai; Raya Khanin; Martin Fleisher; Hans Lilja; Howard I Scher
Journal:  Eur Urol       Date:  2013-07-26       Impact factor: 20.096

4.  Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Authors:  David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Authors:  M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis
Journal:  Ann Oncol       Date:  2015-06-27       Impact factor: 32.976

6.  Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Authors:  Howard I Scher; Glenn Heller; Arturo Molina; Gerhardt Attard; Daniel C Danila; Xiaoyu Jia; Weimin Peng; Shahneen K Sandhu; David Olmos; Ruth Riisnaes; Robert McCormack; Tomasz Burzykowski; Thian Kheoh; Martin Fleisher; Marc Buyse; Johann S de Bono
Journal:  J Clin Oncol       Date:  2015-03-23       Impact factor: 44.544

7.  Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.

Authors:  Cristina Raimondi; Chiara Nicolazzo; Angela Gradilone; Giuseppe Giannini; Elena De Falco; Isotta Chimenti; Elisa Varriale; Siegfried Hauch; Linda Plappert; Enrico Cortesi; Paola Gazzaniga
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

8.  Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Susan Feyerabend; Stefan Aufderklamm; Johannes Mischinger; Ursula Kühs; Valentina Gerber; Jasmin Fetisch; David Schilling; Siegfried Hauch; Arnulf Stenzl; Christian Schwentner
Journal:  Anticancer Res       Date:  2012-08       Impact factor: 2.480

9.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Authors:  Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller
Journal:  Lancet Oncol       Date:  2009-02-11       Impact factor: 41.316

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  20 in total

Review 1.  Novel approaches to target the microenvironment of bone metastasis.

Authors:  Lorenz C Hofbauer; Aline Bozec; Martina Rauner; Franz Jakob; Sven Perner; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2021-04-19       Impact factor: 66.675

Review 2.  Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Authors:  Daniel P Petrylak; E David Crawford
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 3.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

Review 4.  Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.

Authors:  Gareth J Morrison; Amir Goldkorn
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

Review 5.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

6.  GRHL2 suppresses tumor metastasis via regulation of transcriptional activity of RhoG in non-small cell lung cancer.

Authors:  Xiang Pan; Rong Zhang; Caifeng Xie; Mingxi Gan; Sheng Yao; Yubin Yao; Jiangbo Jin; Tianyu Han; Yunhe Huang; Yanlong Gong; Jianbin Wang; Bentong Yu
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 7.  Circulating tumor cell profiling for precision oncology.

Authors:  Mahmoud Labib; Shana O Kelley
Journal:  Mol Oncol       Date:  2021-02-01       Impact factor: 6.603

Review 8.  Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.

Authors:  Vincenzo Di Nunno; Lidia Gatto; Matteo Santoni; Alessia Cimadamore; Antonio Lopez-Beltran; Liang Cheng; Marina Scarpelli; Rodolfo Montironi; Francesco Massari
Journal:  Front Oncol       Date:  2018-09-24       Impact factor: 6.244

Review 9.  The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance.

Authors:  Hassan Dianat-Moghadam; Mehdi Azizi; Zahra Eslami-S; Luis Enrique Cortés-Hernández; Maryam Heidarifard; Mohammad Nouri; Catherine Alix-Panabières
Journal:  Cancers (Basel)       Date:  2020-04-03       Impact factor: 6.639

10.  Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.

Authors:  Xavier Ruiz-Plazas; Esther Rodríguez-Gallego; Marta Alves; Antonio Altuna-Coy; Javier Lozano-Bartolomé; Manel Portero-Otin; Joan Francesc García-Fontgivell; Salomé Martínez-González; José Segarra; Matilde R Chacón
Journal:  J Transl Med       Date:  2019-09-09       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.